Barinthus Biotherapeutics plc
NASDAQ Global MarketTotal Valuation
Barinthus Biotherapeutics plc carries a market capitalization of 24.76M, placing it among publicly traded companies globally. Its enterprise value stands at -31.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 24.76M |
| Enterprise Value | -31.66M |
Share Statistics
Barinthus Biotherapeutics plc currently has 40.85M shares outstanding.
| Shares Outstanding | 40.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.07 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | -0.63 |
| P/OCF Ratio | -0.63 |
Financial Position
Barinthus Biotherapeutics plc maintains a current ratio of 6.05, meaning it holds 6.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.56, indicating elevated leverage, while an interest coverage ratio of -879.39 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.05 |
| Quick Ratio | 5.60 |
| Debt / Equity | 16.56 |
| Debt / EBITDA | -0.25 |
| Interest Coverage | -879.39 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -44.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -169,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Barinthus Biotherapeutics plc's stock has declined approximately -69.2335% over the past 52 weeks. The 50-day moving average sits at 0.67, while the 200-day moving average is 0.76.
| Beta (5Y) | N/A |
| 52-Week Price Change | -69.2335% |
| 50-Day Moving Average | 0.67 |
| 200-Day Moving Average | 0.76 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -44.85M, while operating income came in at -49.52M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -49.52M |
| Pretax Income | -52.50M |
| Net Income | -52.31M |
| EBITDA | -44.85M |
| EBIT | -49.52M |
| Earnings Per Share (EPS) | -1.29 |
Balance Sheet
Barinthus Biotherapeutics plc holds 65.86M in cash and equivalents against 11.01M in total debt, resulting in a net debt position of -65.86M. Total book value stands at -309.63M, with working capital of 60.66M providing operational flexibility.
| Cash & Cash Equivalents | 65.86M |
| Total Debt | 11.01M |
| Net Debt | -65.86M |
| Equity (Book Value) | -309.63M |
| Book Value Per Share | -7.62 |
| Working Capital | 60.66M |
Cash Flow
Barinthus Biotherapeutics plc produced -36.44M in operating cash flow over the past twelve months. After subtracting -32,000.00 in capital expenditures, free cash flow totaled -36.47M - equivalent to -0.90 per share.
| Operating Cash Flow | -36.44M |
| Capital Expenditures | -32,000.00 |
| Free Cash Flow | -36.47M |
| FCF Per Share | -0.90 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -157.54 |
Scores
Barinthus Biotherapeutics plc posts an Altman Z-Score of -6.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.14 |